BMJ - Hidden Data Putting GlaxoSmithKline to the test over paroxetine

Cite this as: BMJ 2013;347:f6754Child and adolescent psychiatryChild and adolescent psychiatry (paedatrics)More topics ArticleRelated contentRead responses (1)Article metricsPeter Doshi, associate editorAuthor [e-mail] antidepressant paroxetine is no stranger to headlines. The drug is now back centre stage as requests for clinical data from one of its trials are testing manufacturer GlaxoSmithKline’s commitment to full transparency, Peter Doshi reportsWhen the Journal of the American Academy of Child and Adolescent Psychiatry(JAACAP) published study 329 in 2001,1 its editors could have had no idea that the paper would spark a controversy, not only about the use of the antidepressant paroxetine in children but also about secrecy in clinical trials. It is a controversy that rages to this day and that goes to the heart of recent campaigns to gain access to drug companies’ trial data.By most accounts, GlaxoSmithKline is leading the pack in its efforts to liberate access to its clinical trial data. It was the first major pharmaceutical company to sign up to the international AllTrials petition calling for all trials to be registered with the full methods and the results reported.2 Whereas companies like AbbVie and InterMune have lodged lawsuits aiming to block access to clinical trial data,3 GSK has forged ahead with a new website enabling third party access to deidentified participant level data “beca...

Source: PharmaGossip - November 15, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs